Edition:
United States

Brainstorm Cell Therapuetics Inc (BCLI.OQ)

BCLI.OQ on NASDAQ Stock Exchange Capital Market

3.39USD
18 Apr 2018
Change (% chg)

-- (--)
Prev Close
$3.39
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
15,041
52-wk High
$5.15
52-wk Low
$2.88

Chart for

About

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its... (more)

Overall

Beta: 1.38
Market Cap(Mil.): $64.65
Shares Outstanding(Mil.): 19.07
Dividend: --
Yield (%): --

Financials

  BCLI.OQ Industry Sector
P/E (TTM): -- 199.23 33.71
EPS (TTM): -0.26 -- --
ROI: -62.76 -0.66 13.09
ROE: -62.76 -2.84 14.92

BRIEF-Brainstorm Cell Received Good Manufacturing Practice Approval From Israel Ministry Of Health

* BRAINSTORM CELL THERAPUETICS - RECEIVED GOOD MANUFACTURING PRACTICE APPROVAL FROM ISRAEL MINISTRY OF HEALTH FOR ISRAELI CONTRACT MANUFACTURING FACILITY

Jan 04 2018

BRIEF-Brainstorm Granted GMP Certification For Marketing-Level Manufacturing Of NurOwn

* BRAINSTORM GRANTED GMP CERTIFICATION FOR A MARKETING-LEVEL MANUFACTURING OF NUROWN® Source text for Eikon: Further company coverage:

Jan 03 2018

BRIEF-Brainstorm Cell Therapuetics names Eyal Rubin CFO

* Brainstorm strengthens executive team: appoints Eyal Rubin as chief financial officer

Nov 02 2017

Earnings vs. Estimates